Comparative Pharmacology
Head-to-head clinical analysis: NEUPOGEN versus ZARXIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEUPOGEN versus ZARXIO.
NEUPOGEN vs ZARXIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. It acts by binding to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and maturation of neutrophils.
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to specific cell surface receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days, or until absolute neutrophil count reaches 10,000/mm³ after nadir. For mobilization of peripheral blood progenitor cells: 10 mcg/kg subcutaneously once daily for 6-7 days.
5 mcg/kg subcutaneously once daily. Round to nearest vial size (300 mcg/0.5 mL or 480 mcg/0.8 mL).
None Documented
None Documented
3.5 hours (range 2.5–4.5 hours) in healthy subjects; terminal elimination half-life is prolonged in patients receiving chemotherapy due to decreased clearance, approximately 5.5 hours.
Terminal elimination half-life is approximately 3.5-4.5 hours in healthy adults; prolonged in renal impairment (up to 40 hours in end-stage renal disease).
Primarily renal; greater than 90% of filgrastim is eliminated via renal excretion as intact protein and degraded metabolites. Biliary/fecal excretion is minimal (<1%).
Primarily renal (70-80% as unchanged drug) via glomerular filtration; biliary/fecal excretion is negligible (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor